Core Insights - Resmed Inc. (RMD) is experiencing strong demand for its AirSense 10 and AirSense 11 sleep devices, with promising international market expansion supported by stable solvency [1][9] - The stock has increased by 5.1% over the past year, outperforming the industry which declined by 3.2%, while the S&P 500 rose by 19.5% during the same period [1] Company Performance - Resmed has a market capitalization of $36.23 billion and an earnings yield of 4.4%, which is favorable compared to the industry's flat yield [2] - The company has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 3.04% [2] Growth Opportunities - The company is focusing on expanding into high-growth international markets such as China, South Korea, India, Brazil, and Eastern Europe, aiming to enhance patient quality of life and reduce healthcare costs [3] - In Q1 FY26, combined sales in the U.S., Canada, Latin America, Europe, and Asia increased by 10% [4] - Global device sales rose by 9% in Q1 FY26, with an 8% increase in the U.S., Canada, and Latin America, and an 11% increase in Europe, Asia, and other markets [5][9] - The AirSense 11 platform is being launched in more countries, including India, and a new version for sleep lab environments has been introduced [6] Financial Health - As of September 30, 2025, Resmed had a long-term debt of $408.7 million, significantly lower than its cash and cash equivalents of $1.38 billion, with a total debt-to-capital ratio of 6.3% [7][9] Challenges - Resmed's operations are affected by macroeconomic conditions, geopolitical instability, and supply chain constraints, which may lead to increased costs and impact profitability [10] - SG&A expenses rose by 9.5% year-over-year in the fiscal first quarter [10] Earnings Estimates - The Zacks Consensus Estimate for RMD's fiscal 2026 earnings per share (EPS) has increased by 0.2% to $10.84, with revenue estimates at $5.58 billion, reflecting an 8.4% increase from the previous year [11]

Group 1: Mineral Resources Ltd (MIN) - The share price of Mineral Resources Ltd (ASX:MIN) has increased by 59.2% since the beginning of 2025 [1] - MIN is a diversified mining company focused on lithium and iron ore extraction in Western Australia [1] - MIN also provides mining and engineering services through its subsidiary, CSI Mining Services, which operates across multiple Australian states [2] - The company differentiates itself from competitors through its in-house engineering and construction capabilities, allowing for greater control in product development [2] Group 2: ResMed (RMD) - ResMed, founded in 1989, specializes in medical equipment, particularly cloud-connectable CPAP machines for treating obstructive sleep apnea [3] - The company operates in over 140 countries and has two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [4] - ResMed's digital health network leverages cloud-connected devices to improve patient outcomes and reduce healthcare costs [5] Group 3: Financial Performance - MIN's revenue has grown at a rate of 12.2% per year since 2021, reaching $5,278 million in FY24, but net profit has decreased from $1,270 million to $125 million, with a reported ROE of 3.2% [7] - In contrast, RMD has seen a revenue growth rate of 13.6% per year, reaching $4,685 million in FY24, with net profit increasing from $475 million to $1,021 million and a reported ROE of 22.7% [7]

Market Overview - The three major U.S. stock indices experienced a decline on December 29, 2025, primarily driven by a drop in large technology shares such as Oracle, Nvidia, and Palantir Technologies, which dampened expectations for a "Santa Claus rally" [1][10] Investment Strategy - Investors are advised to favor low-leverage stocks over high-growth technology stocks due to the recent market sell-off, with companies like Engie SA, Hamilton Insurance Group, Hecla Mining, Resmed, and Siemens Energy being recommended as safer options [2][10] - Low-leverage stocks are characterized by lower financial risk, making them more stable during market volatility [6][9] Low-Leverage Stocks - Leverage refers to the use of borrowed capital for business operations, but excessive reliance on debt can lead to significant losses, especially during economic downturns [4][5] - The debt-to-equity ratio is a key metric for assessing a company's financial risk, with a lower ratio indicating better solvency [7] Company Highlights - **Engie SA (ENGIY)**: Engie operates in the power and energy services sector and recently announced the full commercial operation of its largest onshore wind project, which is expected to enhance its position in the wind energy market. The Zacks Consensus Estimate for 2025 earnings indicates a 28.5% improvement from the previous year [14] - **Hamilton Insurance Group (HG)**: The company reported a 16.5% increase in net premiums and significant improvement in operating earnings, with a Zacks Consensus Estimate suggesting a 20.8% revenue increase for 2025 [15][16] - **Hecla Mining (HL)**: As a leading silver producer, Hecla announced progress on its Polaris Exploration Project, with a Zacks Consensus Estimate indicating a 42.1% revenue increase and a 281.8% earnings improvement for 2025 [17][18] - **Resmed (RMD)**: Resmed received FDA clearance for an AI-enabled medical device aimed at improving CPAP therapy adherence, with a projected 8.4% sales growth for fiscal 2026 [19][20] - **Siemens Energy (SMNEY)**: The company focuses on renewable energy and plans to repurchase shares worth approximately $6.9 billion, with a Zacks Consensus Estimate indicating a 16.9% revenue increase and a 158.2% earnings improvement for fiscal 2026 [21][22]

Core Insights - Boston Scientific (BSX) and Resmed (RMD) are significant players in the global medical devices market, with market capitalizations of $142.4 billion and $35.72 billion, respectively [2] - The medical devices market is projected to grow at nearly 7% CAGR from 2025 to 2030, prompting an evaluation of investment opportunities in both companies [3] Boston Scientific Overview - Boston Scientific is experiencing strong performance in its Cardiovascular and MedSurg segments, with expectations for above-market growth through 2025-2026 [4] - The WATCHMAN device is a leading product in percutaneous left atrial appendage closure (LAAC), with a projected market expansion of approximately 20% in the coming years [5] - The company is gaining market share in electrophysiology, particularly with the FARAPULSE Pulsed Field Ablation System, which received FDA approval for expanded use in July 2025 [6] - Recent acquisitions, including Intera Oncology and Elutia's BioEnvelope business, support Boston Scientific's growth strategy and expansion into high-growth areas [7] - Emerging markets accounted for 15% of Boston Scientific's consolidated net sales in the first nine months of 2025, indicating significant long-term growth potential [8] Resmed Overview - Resmed is witnessing strong demand for its mask portfolio, including the AirFit and AirTouch ranges, and is focusing on direct-to-consumer markets in regions like China and India [9] - The company has launched new variants of its AirTouch F30i mask and continues to see strong sales from its AirSense device platforms [9] - Resmed is advancing AI integration in its digital health products, including the launch of the personal sleep health digital assistant, Dawn, in the U.S. [11] - The company is optimizing operations to improve gross margins and has made acquisitions like Somnoware and Ectosense to support its 2030 growth strategy [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS indicates a year-over-year increase of 21.1% to $3.04, with a slight upward revision in the last 60 days [13] - Resmed's fiscal 2026 EPS consensus estimate of $10.84 reflects a 13.5% improvement over 2025, with a 3.3% increase in estimates over the past 60 days [15] - In the last 12 months, BSX shares have increased by 6.8%, while RMD shares have risen by 5.8% [16] Investment Considerations - Boston Scientific is highlighted for its divisional strength, ongoing momentum with the WATCHMAN device, and strategic acquisitions in high-growth markets [18] - Resmed remains focused on innovation and strong demand for its products, but Boston Scientific is currently viewed as the more attractive investment option based on recent performance [18] - Boston Scientific holds a Zacks Rank 2 (Buy), while Resmed has a Zacks Rank 3 (Hold) [20]

Core Insights - The article highlights significant structural changes in retirement and healthcare financing in the U.S. by 2026, which will impact consumer payment methods for care and competition among medical device companies [1] Policy Changes - The IRS has increased Health Savings Account (HSA) contribution limits for 2026 to $4,400 for individuals and $8,750 for families, up from $4,300 and $8,550 in 2025 respectively [2] - The age-55 "catch-up" contribution remains at $1,000, reflecting cost-of-living adjustments aimed at preserving the tax-advantaged nature of HSAs [3] - Medicare Part B premiums are rising to $202.90 per month, an increase of nearly $18 from 2025, with the Part B deductible increasing to $283 [4] Implications of HSA and Medicare Changes - The rising HSA limits make HSAs more attractive for managing out-of-pocket healthcare costs, while higher Medicare premiums may lead to increased enrollment in Medicare plans and ancillary services [5] - HSAs can be used for both current medical costs and qualified medical device expenses, allowing consumers to save more tax-free dollars for durable medical equipment [6] - Higher premiums may increase demand for technologies that improve disease self-management and prevent costly complications, influencing total care costs [7] Companies Positioned to Benefit - DexCom, ResMed, and Masimo are identified as companies likely to benefit from these trends due to their focus on markets where out-of-pocket costs and reimbursement policies significantly affect adoption [8] - DexCom's continuous glucose monitoring (CGM) systems may see increased adoption as higher HSA limits help patients manage diabetes costs [9] - ResMed's devices for sleep and respiratory care align with the aging Medicare demographic and rising out-of-pocket care needs [9] - Masimo's monitoring tools support preventive care, which becomes more relevant as Medicare premiums rise [9] Company-Specific Insights - DexCom is a leader in CGM systems, providing real-time glucose data that aids in insulin delivery and lifestyle management, with a focus on expanding Medicare coverage for CGM devices [10][11] - Higher HSA limits allow diabetes patients to allocate more pre-tax savings for CGM systems, reducing financial barriers to adoption [12] - ResMed specializes in devices for sleep-disordered breathing, with rising premiums incentivizing seniors to use HSAs for optimal therapy devices [15][16] - Masimo develops non-invasive monitoring systems, with increased demand for preventive monitoring as Medicare beneficiaries face higher premiums [18][19]

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [2] - The company operates globally with over 10,000 employees and a presence in more than 140 countries, divided into two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [3] - ResMed's products include industry-leading CPAP machines and software for durable medical equipment, focusing on out-of-hospital care [3][4] Market Performance - The ASX:RMD share price has decreased by 2.0% since the start of 2025 [1] - The S&P/ASX200 Healthcare Index has returned -4.53% per year over the last 5 years, contrasting with a 5.51% annual return from the broader ASX 200 [5] Revenue Stability - Healthcare spending is considered essential, leading to stable and consistent revenue streams, often referred to as 'sticky' revenue, which remains resilient during economic downturns [6] - Historical performance indicates that healthcare was the best-performing sector during the Global Financial Crisis (GFC) [6] Growth Potential - Global healthcare spending, particularly in the US, is projected to grow significantly, with estimates of 7% annual growth from 2022 to 2027, reaching US$819 billion [7] - Sub-sectors such as healthcare IT and SaaS are expected to see revenue growth exceeding 15% per year from 2024 to 2030, attracting investor interest [8] Ethical Investment Trends - A Morgan Stanley survey indicates that over half of investors plan to increase their allocation to sustainable investments in 2024, positioning healthcare sectors favorably for attracting new capital [9] Valuation Insights - ResMed shares currently have a price-to-sales ratio of 5.08x, below the 5-year average of 8.70x, suggesting that shares may be undervalued or that sales have increased [11]

Core Viewpoint - Resmed will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its commitment to innovative health technologies [1]. Company Overview - Resmed (NYSE: RMD, ASX: RMD) develops health technologies aimed at improving the quality of life for individuals in 140 countries [3]. - The company focuses on AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare [3]. - Resmed envisions a future where individuals can achieve better sleep and breathing through personalized care delivered at home [3]. Event Details - The presentation will be made by Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer [1]. - Access to the live audio-only webcast of the event will be available on Resmed's investor relations website, with a replay accessible for 30 days post-event [2].

Core Insights - Resmed has received FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort, set to launch in early 2026 for new users of the myAir app paired with the AirSense 11 device [1][9] - Smart Comfort is designed to enhance the user experience in CPAP therapy by utilizing AI and real-world sleep data to provide personalized comfort settings [2][5] Company Developments - Resmed's Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings for patients with obstructive sleep apnea (OSA), which affects an estimated 61 million people in the U.S. [3][9] - The company currently has a market capitalization of $37.44 billion, with a projected 13.2% increase in fiscal 2026 earnings according to the Zacks Consensus Estimate [4] Product Features - Smart Comfort addresses common therapy issues such as comfort and mask fit, promoting long-term adherence to CPAP therapy by leveraging machine-learning algorithms and over 100 million nights of de-identified sleep data [5][6] - The device settings include features that ease users into therapy, adjust pressure gradually, and reduce pressure on exhalation, developed with clinical oversight and ethical data use [6][7] Market Outlook - The global sleep apnea device market is valued at $7.11 billion in 2025, with a projected compound annual growth rate of 7% through 2034, driven by the rising prevalence of sleep apnea and advancements in medical technology [11] - Resmed's recent initiatives, such as the launch of the Sleep Institute, aim to advance the science of sleep health and support policy decisions [12] Stock Performance - Following the announcement of Smart Comfort, Resmed's shares dropped 2.5%, closing at $250.04, but the product is expected to support a rebound in stock performance [3] - Year-to-date, Resmed shares have increased by 9.3%, outperforming the industry average of 3.2% [13]

Core Insights - Resmed has received FDA clearance for its AI-enabled medical device, Smart Comfort, aimed at improving CPAP therapy adherence for patients with obstructive sleep apnea (OSA) [1][2][4] Group 1: Product Overview - Smart Comfort is the first FDA-cleared device that recommends personalized comfort settings for CPAP therapy, launching in early 2026 in a limited U.S. beta version [2] - The device utilizes machine-learning algorithms based on over 100 million nights of de-identified sleep data to tailor comfort settings for users [3] - Smart Comfort aims to address common therapy issues such as comfort and mask fit, promoting long-term adherence to CPAP therapy [3] Group 2: Clinical and Market Impact - The FDA submission was supported by evidence showing that users whose comfort settings matched Smart Comfort recommendations had higher engagement and sustained therapy adherence compared to those using default settings [4] - OSA affects an estimated 61 million people in the U.S., projected to rise to nearly 77 million by 2050, highlighting a significant market opportunity for Resmed [5] - CPAP therapy is recognized as the gold standard treatment for sleep apnea, significantly reducing health risks associated with untreated OSA [5] Group 3: Benefits for Healthcare Providers - Smart Comfort streamlines user setup and follow-up for healthcare providers, allowing clinicians to focus more on clinical decision-making and patient support [6] - The device helps standardize comfort settings, enhancing user confidence that their therapy is personalized [6] Group 4: Company Vision and Commitment - Smart Comfort is part of Resmed's broader connected, personalized sleep-health ecosystem, which integrates AI and cloud-connected devices to enhance therapy efficacy [7] - Resmed is committed to responsible, data-driven innovation to improve sleep health and empower users [8]

Core Insights - ResMed Inc. has a market capitalization of $37.4 billion and specializes in medical devices and cloud-based software for respiratory disorders [1] - The company operates in two segments: Sleep and Breathing Health, and Residential Care Software, providing a range of solutions from sleep diagnostics to healthcare software platforms [1][2] Financial Performance - ResMed reported Q1 2026 results with a 9% revenue growth to $1.34 billion, a 280 basis points adjusted gross-margin expansion, and a 16% adjusted EPS growth to $2.55 [5] - The company generated $457 million in operating cash flow and continued share repurchases and dividends, indicating strong operational strength and investor confidence [5] Stock Performance - ResMed's stock has decreased by 12.7% from its 52-week high of $293.81 and has declined 7.4% over the past three months, underperforming the S&P 500 Index, which increased by 6% in the same period [3][4] - Year-to-date, RMD stock is up 12.2%, lagging behind the S&P 500's 16.8% gain, and has increased 7.2% over the past 52 weeks compared to the S&P 500's 13.1% return [4] Market Position - ResMed's stock has a consensus rating of "Moderate Buy" from 19 analysts, with a mean price target of $291.31, representing a 13.5% premium to current levels [6] - The company has outperformed its competitor, Intuitive Surgical, Inc., which has gained 5.1% over the past 52 weeks and 10.2% year-to-date [6]